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Definitions: 
ASCUS: This represents a cellular morphology in which changes are noted that appear worse 
than those that can be identified as reactive changes, but fall short of the morphologic criteria for 
squamous intraepithelial lesion 
AGC: Glandular cell abnormalities may be atypical endocervical, endometrial or glandular cells, 
this is a clinically important category as it can be associated with a higher proportion of high 
grade lesions. In this study I will use AGUS, as the NHLS still uses this terminology. AGUS is 
the same as AGC, but AGUS is an from the older Bethesda 1988 terminology. 
ASC-H:  It is diagnosed when atypical squamous cells exhibit some equivocal features 
suggestive of HSIL but not sufficient to be called HSIL.      
CIN 1: Abnormal cell growth which is confined to the basal third of the epithelium.  
CIN 2: Abnormal cell growth which is confined to the basal two-third of the epithelium 
CIN 3: Abnormal cell growth occupies the full thickness of the epithelium           
Cervical dysplasia: precancerous condition in which abnormal cell growth occurs on the surface 
lining of the cervix or endocervical canal, the opening between the uterus and the vagina, it is 
also called cervical intraepithelial neoplasia. 
Papanicolaou: Papanicolaou stain includes both acidic and basic dyes. The  polychrome stain 
involves 5 dyes and allows separate visualization of all aspects of the cell; cytoplasm, nuclear 
material and keratin.  
LSIL: This encompasses the presence of human papilloma virus and mild dysplasia/CIN1 
HSIL: This encompasses moderate and severe dysplasia (CIN2 and CIN3) as well as carcinoma 
in situ. 
LLETZ: it is a procedure aimed at removing the transformation zone using a wire loop. 
VAS: This is a measurement instrument that tries to measure a characteristic or attitude that is 
believed to range across a continuum of values and cannot easily be directly measured 
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Abstract  
Prevention of cervical cancer in SA became a National priority in 2003 and guidelines for 
screening using the Papanicolaou (Pap) smear was introduced. Women with abnormal Pap 
smears are referred to colposcopy according to national guidelines.  Chris Hani Baragwanath 
Academic Hospital has a see and treat policy where all women who are referred are evaluated 
and when the colposcopy findings are that of a CIN2 or more severe a Large Loop Excision of 
the Transformation zone is performed. The complications and experience of women in this 
setting is unknown 
Objectives 
The main objective of this study was to evaluate the experiences, immediate and early 
complications following colposcopy and a LLETZ procedure. 
Methods 
This was a prospective, descriptive study. Demographic data, contraceptive use, HIV status, 
cytology findings and histology results were extracted from the clinic database in 150 women 
who had a LLETZ performed.  A questionnaire was used to record women‟s experiences and the 
complications of the procedure.  A VAS score was used to quantify pain 
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Results  
The mean age was 40.41(SD±9.51), the mean parity 2.17(SD±1.34). Eighty- three (55%) women 
were HIV positive. The mean CD4+ count was 366.90µl/?? (SD±214.90),.Of 120 women who 
answered the question about smoking, 12(10%) were smokers. The cytology was reported as 
normal (1(0.74%)), ASCUS (4(2.66%)), ASC-H (10(6.67%), LSIL (18(12.00%)), HSIL 
(86(57.33)), AGUS (1(0.74%)) , suspected invasion (4(2.96%)), and squamous cell carcinoma 
(1(0.74%).  Pap smears had not been recorded in (25(16.67%)) patients.  There were 115 women 
who had a complete colposcopy diagnosis recorded. This was normal (3(2.08%)), CIN1 
(22(19.13%)), CIN2 (50(43.48%)), CIN3 (27(23.48%)), and micro invasion (3(2.00%)).  
Histology results were available for 144 patients after LLETZ, 2(1.39%) had normal histology, 
49(34.03%) women had CIN1, 35(24.31%) had CIN2, 54(37.50%) had CIN3, 1(0.68%) had 
micro invasion and 3(2.08%) women had a malignancy.  Fifty women (33.33%) reported pain, 
121 (80.67%) bleeding, and 94(62.67%) had a discharge in the 4 weeks after the procedure  
Eighty-Five (56.07%) women were anxious, 1(0.67%) was feeling bad about the results, the 
biggest fear among patients was cancer (55,08%), only 1(0.67%) had a bad experience with the 
actual colposcopy, and more than 90% of patients said that they preferred local anaesthesia over 
general anaesthesia. 
 
Conclusion 
Pap smear screening, colposcopy and treatment are associated with medical and emotional 
morbidity. This has to be balanced with a proven reduction in cervical cancer. 
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Chapter 1 
1.0 INTRODUCTION 
Cervical cancer is still the most common cancer of women on the African continent.
1
 According 
to the International agency for research on cancer (IARC), cervical cancer accounts for 23% of 
all cancers in South Africa (SA).
2 
Cervical cancer is the second most common cancer among 
South African women, with 1 in 41 women developing the disease in her life time.
2
 Cervical 
cancer is a preventable cancer with screening and treatment of cervical cancer precursors.
3 
Prevention of cervical cancer in SA became a national priority in 2003. Guidelines for screening 
were developed using the WHO recommendations.
1
 The South African national policy on 
cervical cancer screening allows for three successive Pap smears from the age of 30 years.
1
 
However it is estimated that screening coverage is as low as 13% in some provinces.
1
 The 
prevalence of cervical cancer precursors is approximately 7.4% for LSIL and 4.6% for HSIL in 
SA.
4 
 Women with abnormal Pap smears are referred to a colposcopy clinic for diagnosis 
according to National guidelines. 
The colposcopy clinic at CHBAH has a see and treat policy, where all women with abnormal 
cervical cytology coupled with a colposcopy diagnosis suggesting Cervical Intraepithelial 
Neoplasia 2(CIN2) or worse  or inadequate colposcopy are treated with large loop excision of the 
transformation zone(LLETZ) at the first visit. 
The reason for treating at first visit was a long waiting time and because of the high number of 
women that do not attend the clinic for their appointment. In 2005, 80(34.6%) patients out of 231 
who were booked for colposcopy did not come for the visit.
5 
Women defaulted after treatment 
with 9.9% not returning for their histology results and 38.5% not returning for their 6 month visit 
at this clinic in Soweto.
5 
 Overtreatment is one of the concerns of a see and treat clinic. The proportion of women who had 
normal histology at LLETZ in this clinic was 3.30%.
6 
Immediate complications occur in less 
13 
 
than 4% of these patients at CHBAH.
5, 6
 However we do not know what proportion of women 
have complications in the 4 weeks after treatment and what their experiences are.   
The aim of this study is therefore to find out women‟s experiences and the complications in the 4 
weeks after LLETZ. 
 
1.1 LITERATURE REVIEW 
 In 2004 cervical cancer made up 18.5% of female cancers, with approximately 5000 new cases 
reported annually.
7 
We have come a long way in understanding the natural history of cervical 
cancer and this has made it possible to prevent cervical cancer. Treatment of premalignant 
disease of the cervix has reduced cervical cancer by 95%, but the process of screening, diagnosis 
and treatment are associated with complications.
8
 In this chapter, I will discuss primary and 
secondary screening, diagnosis and treatment, followed by a discussion on the complications of 
diagnosis and treatment. This will be followed by the problem statement and aims of the study. 
Human papillomavirus (HPV) infection appears to be a necessary factor in the development of 
cervical cancer.
9, 10
 There are around 40 HPV types associated with genital infection and they are  
classified according to their oncogenic potential : Low risk: 6, 11, 40, 41, 42 ,43, 44, 54, 61, 72, 
73,81, High risk: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 62, 68,  and 82, Probable high 
risk: 26 ,53, 66, 69 and 74.
4, 11
 HPV 16 and 18 are the most oncogenic and are associated with 
approximately 70% of cervical cancers worldwide.
11
 Most HPV infection will be cleared, 
however in those women where it persists there is a risk of dysplasia and cervical cancer. It takes 
approximately 10 to 30 years from infection with HPV to the development of cervical cancer.
12 
Risk factors for cervical cancer are smoking, human papilloma virus (HPV), steroid 
contraceptives, herpes simplex type 2, chlamydia trachomatis, early sexual debut, multiple 
sexual partners, immunosuppression and poverty.
13
 Figure 1.1 below shows the factors that may 
lead to persistent HPV and cervical cancer. 
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Figure 1.1 Schematic representation showing the natural history of cervical cancer. 
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Cervical intraepithelial neoplasia (CIN) is asymptomatic and essentially unrecognizable on 
inspection or palpation.
14 
Occasional signs and symptoms;
14 
 Abnormal bleeding 
 Spotting after intercourse 
 Vaginal discharge 
 
1.2 PREVENTION 
Prevention of cervical cancer may be primary or secondary. Primary prevention is possible using 
the HPV vaccination. There are 2 vaccines which are at present registered for use in SA; a 
quadrivalent  vaccine with HPV 6/11/16/18  and a bivalent  vaccine with HPV-16/18 . Both 
vaccines protect against infection from HPV- 16 and HPV-18, which are associated with 70% of 
cervical carcinoma.  However, the vaccines are not as effective in women with previous HPV 
exposure.
15
Both vaccines are recommended for women between the ages of 11 and 26years.
15 
 Other modalities for primary prevention are condoms, circumcision, abstinence or sticking to 
one trustworthy partner.
16 
Secondary prevention of cervical cancer is by finding and treating cervical cancer precursors. 
There are many different methods of screening such as HPV DNA testing, visual inspection with 
acetic acid or Lugol‟s Iodine and Pap smears.17, 18 
Screening for high risk HPV is now an accepted modality of screening in other countries.
17, 19
 
The sensitivity of HPV testing is close to 100% due to the ability of PCR to detect HPV DNA 
even when present in minute quantities.
1, 17, 19
 It is expensive, and it needs high technology to be 
performed and in low resourced countries is not affordable.
18
  
HPV DNA test is very beneficial in a sense that, a negative HPV test, ensures that the risk for 
CIN3 or cervical cancer remains low for at least 5 years, and it accurately predicts future disease, 
grants self - sampling opportunities in populations with limited health care facilities.
18, 20 
16 
 
Some problems using HPV testing as a screening test is how you counsel patients on what is 
wrong and what are their chances of developing cancer. HPV DNA testing has high sensitivity 
and lower specificity, and the detection rate of cervical lesions at the next screening round is 
lower compared to cytology based screening.
18
  
 A study in Cape Town comparing VIA, HPV testing and Pap smears showed that VIA was the 
most poorly performing test.
21
 However it has been used with some success in Malawi and other 
countries and some other countries. VIA in these has been used with immediate treatment.
22
  
Screening for cervical cancer precursors using the Pap smear has been credited for dramatically 
decreasing the incidence and mortality due to cervical cancer in developed countries.
1, 9,18,20,22
 
However, the sensitivity of Pap smear is between 55% and 80% for cervical cancer precursors.
1, 
9, 22 
In SA, screening in the public sector is performed using mainly the conventional Pap smear. Pap 
smears are reported using Bethesda classification.
21
  
Referral to colposcopy is the next step in management of a patient with abnormal Papanicolaou 
test in SA. It is necessary in order to make a diagnosis and then direct treatment. 
The most important indication for colposcopy in modern practice is a positive screening test for 
cervical precursor lesions.     
The cornerstone of colposcopic practice is take a colposcopically directed punch biopsy, to 
confirm the colposcopic diagnosis. Treatment can then be planned and over-treatment and 
undertreatment may be  averted. Colposcopy on its own without biopsy may miss one-third of 
high grade lesions.
23, 24
 A punch biopsy is also necessary to confirm or exclude invasive disease 
in patients undergoing ablative treatment.
25, 26
 There is also growing concern about a single 
punch biopsy, a recent Norwegian study of 520 women, whose colposcopy directed biopsy was 
reported negative found that on follow up biopsy 78(23.8%)  of women to have CIN2 and 
more.
27 
There are many clinics that now practice a “see and treat” or one stop approach for woman with 
an abnormal cytology report. The strategy is often operator dependent with the colposcopist 
making the decision on whether to take a punch biopsy or LLETZ biopsy. 
17 
 
 Studies suggest that women who undergo colposcopy have raised levels of anxiety before and 
during the procedure.
28
  
Although this is an effective treatment around 15% of patients will have persistence /recurrence 
on cytological follow up.  
 
1.3 TREATMENT 
There is national and international consensus that the majority of the procedures used to treat 
premalignant disease of the cervix can be performed in an outpatient setting. The National 
Health Service guidelines (United Kingdom) for the treatment of premalignant lesion suggests 
that “more than 80% of these procedures be performed in an outpatient setting”.29 
Treatment may be either ablative or excisional, ablative treatments may be performed in an 
outpatient setting under local anaesthetic. Some excisional methods such as LLETZ may also be 
performed in an outpatient setting.  The table below shows the different methods used for 
treatment. One of the pitfalls of the see and treat policy is that women may be over treated .See 
and treat policy should be confined to patients who have unequivocal CIN on cytology and 
colposcopy. 
TABLE 1.1 
ABLATIVE EXCISIONAL 
Cryotherapy LLETZ 
Cold coagulation Lazer conization 
Laser vaporization Cervical cone biopsy 
Electrosurgery Hysterectomy 
 
Complications of ablative and excisional  methods include the following; mild lower abdominal 
pain, excessive dark brown discharge, severe perioperative bleeding, post-operative pain, 
fainting (vasovagal reaction) and infection.
30-32
 Table 1.2 below summarizes the differences 
between the different management options. 
18 
 
Cryotherapy, was first used by an English physician James Arnott, he used extreme cold locally 
for the destruction of tissue. It involves the application of liquid nitrogen or carbon dioxide to the 
cervix. This causes the cervical tissue to freeze and burst, which destroys the cells.
33 
Cold coagulation; is a method that uses electricity to heat a thermosound to temperatures of 100-
120ºC, and causes an ablation of a cervical lesion by „boiling‟ the cells.34-36 
Laser vaporization, uses a carbon dioxide laser which is directed at the cervical lesion under 
colposcopic guidance. The laser energy is absorbed by water that‟s contained in the tissue, and 
the tissue is destroyed by vaporization. 
Electrsurgery/Diathermy is a technique that uses a needle that is attached to a cautery device to 
destroy a cervical tissue. 
The excisional methods LLETZ, cold knife cone and laser cone all aim at removing the 
transformation zone. LLETZ uses thin wire loop with an electric current (a blended current that 
can coagulate and cut). 
Hysterectomy, which entails the removal of uterus, was previously performed for cervical 
precursor lesions and has largely been replaced by conservative treatments e.g LLETZ. 
It can still be considered in special situation, HSIL in a postmenopausal woman or when there is 
involved margin post LLETZ in a patient who has completed her family or concurrent 
gynaecological disease. 
 
TABLE 1.2 
Treatment Advantages Disadvantages Complications 
Ablative   
Cryotherapy Cheap 
Can be performed 
under LA in an 
outpatient setting. 
Easy to learn  
Higher failure rate 
when treating large 
lesions 
Need a Biopsy 
Not suitable for 
women with large 
lesions occupying 
more than 75% of the 
Discharge 
Pain 
Bleeding 
Infection  
Delayed bleeding
37 
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ectocervix, extending 
to the vaginal wall,
38
 
not suitable for 
atrophic cervix 
 
 
Can be done with or 
without  
anaesthesia/analgesia 
 
 
Inadvertent 
destruction of an early 
invasive disease 
missed on colposcopy 
Need a biopsy 
Not suitable for 
woman with lesions 
occupying  more than 
75% of the 
ectocervix[European 
guidelines]
39 
 
Excessive vaginal 
discharge 
Mild lower abdominal 
cramps 
Vaginal bleeding 
Laser Ablation Can be performed 
under LA in an 
outpatient setting 
Need a Biopsy 
Expensive 
Time consuming 
Tissue charring 
Discharge 
Pain 
Bleeding 
Infection 
 
 
Excisional   
LLETZ Cheap 
Can be performed 
under LA in an 
outpatient setting 
Will obtain Tissue for 
Histology 
Easy to Learn 
 
Overtreatment when 
used in a see and treat 
clinic 
 
Post operative pain 
Dark brown mucus 
discharge 
Severe perioperative 
bleeding 
Infection 
 
Laser Cone Will obtain Tissue for 
Histology 
Expensive 
Time consuming 
Discharge 
Pain 
Bleeding 
Infection 
 
Cold Knife Cone Needs to be done 
under GA 
Will obtain Tissue for 
Histology. 
Expensive 
Patient has to be an 
in- patient or could be 
done in a day clinic 
Bleeding 
Hysterectomy Will obtain Tissue for 
Histology 
 
Can only be done in 
theatre under GA 
Not advisable for 
those who still require 
fertility 
Long hospital stay 
Complications of 
hysterectomy 
20 
 
The consensus is that local excisional techniques are by far superior to ablative techniques. They 
allow excised tissue to be evaluated histologically, however not all are of low cost. The duration 
is short whereas ablative techniques destroy the transformation zone and require accurate pre-
treatment biopsy at a separate occasion, however they both have the same efficacy in eradicating 
cervical lesions. In some places they do not do a biopsy but use cryotherapy immediately.
40 
Complications of ablative and excisional methods include the following, mild low abdominal 
pains, excessive brown discharge, severe operative bleeding, post-operative pain, fainting 
(vasovagal reaction) and infection 
The immediate and early complications of LLETZ have been previously reported. Immediate 
complications, are adverse effects occurring during the procedure and early complications occur 
after the procedure up to 4 weeks following the procedure, however both can overlap. 
Immediate complications are;
 
 Vaginal bleeding 
 Pain 
 Bowel injury 
 Discomfort 
 Cramps 
Early complications ; 
 Vaginal bleeding 
 Vaginal discharge 
 Pelvic inflammatory.41 
One randomised study looking at comparison between safety of cryotherapy and LLETZ , found 
that women who had LLETZ were more likely to  have secondary bleeding (79% vs 40%) , 
offensive discharge(79% vs 68.2%) and less likely to have a watery discharge (78.5% vs 
92.4%).
42 
An Indian study evaluating the effectiveness, safety and acceptability of „see and treat‟ with 
cryotherapy in 2513 women, found that 25(2.1%) patients had mild pains or cramps during or 
21 
 
after the procedure, 19(1.6%) had a malodorous vaginal discharge, 9(0.7%) had mild bleeding or 
spotting, 3(0.2%) had delayed bleeding and 2(0.2%) had a fever. Early complications in this 
group were reported as local cervical infection in 14(1.4%), cervical tenderness in 5(0.5%), 1 
(0.1%) had severe pelvic cramps and low abdominal pains which required medication. None of 
patients required blood transfusion or presented with cervical stenosis. 
A study by Chan et al,
43
 of  185 women who had a LLETZ for CIN from 1992 through 1994, and 
were followed up until 1995 found that  anaesthesia was according to patient‟s request, however 
the standard anaesthesia was a local anaesthetic with lignocaine 1%.  Nine patients were 
admitted because of persistent vaginal discharge.  
Two (1.1%) patients had haemorrhage within 24 hours after the procedure and were admitted. 
Cervical stenosis developed in one patient, who presented with amenorrhea and cyclical 
abdominal pain, and ultrasound revealed haematometra and haematosalpinx, she subsequently 
had cervical dilatation. 
 In 2009 Sharp et al 
31
 reported on the frequency of after effects by women following 
colposcopy, cervical biopsies and LLETZ. This was a randomised controlled trial of 929 women 
with LSIL on cytology. A questionnaire was completed 6 weeks after the colposcopy by 750 
women. Those who had colposcopic examination only, 14-18% reported pain, bleeding or 
discharge.  In those who had biopsy and colposcopy, 53% had pain, 46% had discharge and 79% 
had bleeding. In those who had LLETZ, 67% had pain,  63% had a discharge and 87% had 
bleeding. Bleeding and discharge was longer in women who had  LLETZ, however the duration 
of pain was similar across the groups. 
Damage to the stroma and scarring of the cervix may lead to the late complications such as 
cervical stenosis, haematometra, cervical incompetence, late miscarriages, preterm labour, low 
birth weight and spontaneous rupture of membranes.
43
  
Studies have shown that, pregnancy – related morbidity occur with both ablative and excisional 
techniques.
44, 45 
After conisation, (LLETZ, cold knife and electrosurgery) perinatal mortality increases as result 
of preterm delivery.  After one conisation preterm delivery before 37 weeks the adjusted odds 
22 
 
ratio (AOR) was 2.8(95%CI 2.3-3.5); and preterm labour before 28weeks the AOR was 
4.9(95%CI 2.5-9.7) compared with no conisation.  After 2 conisations the AOR for preterm 
labour before 37 weeks was 9.9(95%CI 6-17) and the AOR for preterm labour before 28weeks 
was 9.8(95%1.4-70) compared with no conisation. The risk of perinatal mortality after one 
conisation increases by 2.8 fold.
46 
Another study assessing the risk of preterm labour following LLETZ has been reported by Poon 
et al, comparing 473 women who had LLETZ with 25772 without LLETZ spontaneous preterm 
labour before 34 weeks was higher in those who had LLETZ (3.4% versus 1.3%),and cervical 
length was shorter in patients who had a LLETZ procedure. Even after adjustment of maternal 
risk factors e.g smoking, previous preterm labour, LLETZ remained a risk for spontaneous 
preterm labour.
47 
Psychosocial morbidity following colposcopy in women with an abnormal Pap smear has been 
reported.  Procedures for treating premalignant lesions of the cervix can have adverse 
psychological outcome. Anxiety has been reported by several studies in women following 
colposcopy.
48-51
The prevalence of anxiety was higher in women post- colposcopy than pre-
colposcopy. Depression ranged from 7% to 22% at the first assessment time point post 
colposcopy.
49-54
 Other studies on colposcopy, found depression to be higher in the group having 
colposcopy than control group.
50-55
 One third of women had procedure related distress at the first 
assessment point.
50-56
 Fears about cancer and future fertility was found in one-quarter of women 
and one third were fearful about future infertility post colposcopy and this was lower those 
women reporting these fears pre-colposcopy.  
Studies were inconsistent regarding psychosexual functioning after colposcopy which includes; 
pain and lubrication during sexual intercourse, sexual satisfaction, sexual desire and frequency of 
intercourse.
57-63
  
The level of anxiety in patients undergoing screening for premalignant disease of the cervix can 
also be compared with other screening methods e.g  mammography. Women who receive 
communication about their negative mammography results have less anxiety, whereas those who 
are recalled for further testing have more anxiety. Women with false - positive results had more 
breast cancer specific worry (49% vs. 10%).
64 
23 
 
Anxiety levels were also greater in women who received a diagnosis of CIN 2/CIN 3 than in 
women with a lesser diagnosis at colposcopy.
65 
 
Little is known about the predictors and psychosocial factors influencing the anxiety.
66, 67
 A 
Prospective study of 100 Swedish women compared to 100 controls, looked at psychological 
factors influencing anxiety in women referred for colposcopy. They found that anxiety and 
depression scores were higher in the colposcopy group than the control group. Sixty one percent 
of women studied, did not know why they had had a cervical smear. Fifty-two percent feared 
they had cancer and their level of anxiety was high. Anxiety was higher in women with partners 
and in those who received letters mentioning some changes in their cervical smear.  
Women have expressed worry about fertility, colposcopy, sexual problems and gynaecological 
examination.
68, 69
 However there is not much following colposcopy with immediate LLETZ as is 
practiced in this clinic.  This information would help in determining whether the complications 
have been underestimated. 
 
1.4 Problem statement and Justification for the study 
CHBAH has a see and treat clinic, where women with an abnormal cytology and a colposcopy 
diagnosis of CIN2 are treated immediately. Overtreatment (no dysplasia on histology was found 
in 3.4% of women treated at this clinic in 2008.
5
 LLETZ is associated with immediate 
complications of pain and bleeding and early complications of bleeding, discharge and pain. Late 
complications of stenosis, pregnancy related complications and infertility are well known.
41
  
The reason for a having a “look and LLETZ” clinic has many advantages and whilst the 
complications are known in other countries. The early complications and experiences of women 
in the first 4 weeks after a LLETZ procedure in this population is unknown. We are not sure 
about the severity and duration of bleeding and discharge in women treated with LLETZ at this 
clinic. 
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Such data would make an important contribution to the debate concerning the relative benefits 
and harms of different management options at colposcopy. It may also contribute to the 
counselling of women with abnormal Pap smear that are referred to colposcopy.   
 
 
1.5 General Objective 
To describe the immediate and short term complications and experiences in women who have 
had a LLETZ for cervical dysplasia at the colposcopy clinic at CHBAH between September 
2014 to March 2015. 
 
1.6 Specific  Objectives 
To describe the Demographics, Pap smear results, Colposcopy findings and histology results in 
women who agree to have LLETZ under LA between the study periods. 
To describe the complications in the first 4 weeks after LLETZ. 
To describe women‟s experiences of the LLETZ procedure. 
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Chapter 2 
2.0 METHODS: 
 2.1 Setting 
Chris Hani Baragwanath Academic Hospital is a secondary and tertiary hospital serving the 
population of Soweto of about 1.3 million people.
70
 It also sees patients from surrounding areas 
and is a referral hospital for 7 community health centres and 56 local clinics. At the time this 
study was performed it was the referral hospital for 3 district hospitals and 4 regional hospitals.  
The department of Gynaecology sees approximately 3000 patients a month in the outpatient 
department. There are 68 in-patient beds for Gynaecological problems. The colposcopy clinic 
sees 50 new patients every week. 
 
2.2 Study Population 
The study recruited 150 women over the age of 18 referred to colposcopy clinic from primary 
health centres, community health centres and general practitioners. Most of these women would 
have had screening Pap smears which have been performed by nurse practitioners at a primary 
health care level. Most Pap smears have been performed by National Health Laboratory 
Services(NHLS). This is an accredited laboratory that services South African public health care 
facilities. It has stringent internal and external quality control mechanism in place. The Pap 
smears are reported using the Bethesda Classification.    
The referral criterion was according to Cervical Cancer Prevention guidelines. Any woman with 
an abnormal cervix on clinical examination is referred urgently irrespective of the Pap smear 
result. Those women with a report of HSIL, ASC-H, persistent LSIL or persistent ASCUS, were 
referred to the colposcopy clinic. HIV infected women with any abnormal Pap smear were also 
referred to the colposcopy clinic (Appendix 1).  
Women were counselled prior to the Colposcopy, occasionally at the referral clinic and again at 
the colposcopy clinic. They were also counselled about the LLETZ procedure.  They signed 
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written consent for the procedure. They were also given an information sheet which explains the 
procedure and describes the complications that may occur. Those who agreed to have a LLETZ 
under LA if indicated were eligible for recruitment. They were recruited on the day of LLETZ, 
by the doctor working at colposcopy clinic. 
 
2.3 Procedure  
Colposcopy was performed by a specialist gynaecologist or registrar under supervision. The 
saline technique was used and the colposcopic diagnosis was recorded using the modified Reid 
score. A subjective impression of the lesion was also recorded by the colposcopist. The 
colposcope used was a Liesegang colposcope. 
The patients were placed in lithotomy position for the colposcopy and the colposcopist decided 
on whether a punch biopsy or a LLETZ needs to be performed. Generally all women with an 
abnormal cytology report coupled with a colposcopic impression of CIN2 or worse or an 
inadequate colposcopic examination were treated with a LLETZ. In those women where 
colposcopy was CIN1or normal a punch biopsy or small LLETZ just for diagnosis was 
performed.  
A cervical block was performed using 2% lignocaine and adrenaline (1:80 000). Two percent 
lignocaine was injected at 5 and 7 O‟ clock and then in a circular fashion using dental syringe 
and a 27 gauge/38mm needle.  In those women where a LLETZ was indicated, the colposcopist 
decided on a size of the loop depending on the size of the lesion and the transformation zone.  
Loops that were used were round loops with a diameter of between 10mm and 25mm and depths 
of between 10mm and 20mm. Alternatively C-loop was used with the diameter of between 
11mm and 12mm and depths of between 10mm and 18mm, the aim was to excise the 
Transformation zone.  The Finess11 was used with a foot or hand control.  
The lesion was cauterised after excision only to control bleeding with a ball which was either 
3mm/5mm.  Sexual intercourse was discouraged for at least 4 weeks. 
The patients were asked to come back in 4 weeks for the results of the histology. The histology 
specimens were sent in formalin to the NHLS. 
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2.4 Sample size 
This was a descriptive study and a sample size was not calculated. 150 women were recruited. 
This was a convenience sample. 
 
2.5 Study Design 
This was a prospective cross sectional study of women attending the colposcopy clinic at Chris 
Hani Baragwanath Academic Hospital. 
 
2.6 Data Management 
Data was obtained using a questionnaire, some questions were asked on the day of the procedure 
and some were asked after 4 weeks.  The questionnaire was piloted on 10 patients. Some 
information was extracted from the colposcopy database. Information is prospectively entered on 
the colposcopy database. 
Variables: Age, parity, HIV status, CD4 count, smoking, Cytology results, histology results, and 
colposcopy diagnosis were obtained from the colposcopy data base. 
Patient‟s experiences and complications were obtained using the questionnaire. The researcher 
administered all the questionnaires. The questionnaire was in English, but the researcher was 
able to speak 6 languages and was able to translate some questions. 
 
2.7 Statistics 
Data was entered onto a Microsoft excel data sheet which was then exported to the STATA 
14.1(StataCorp, 4905Lakeway Drive,College Station, Texas 77845 USA) statistical package.  
Continuous variables were presented using means and standard deviations or medians and 
interquatile ranges. Categorical variables were described using frequencies and percentages. 
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For analytical statistics the student t- test was used to compare continuous variables and the chi2 
to compare categorical variables.  The Fisher‟s Exact was used for those comparisons where 
there the numbers were less than 10. Significance was set at 0.05 
 
2.8 Funding 
The researcher funded the entire research process and there was no third party involvement from 
commencement to completion. 
 
2.9 Ethics 
Ethics approval for this study was granted by University of the Witwatersrand HREC 
(M140632).    Permission to do the study in this hospital was obtained from the Chief Executive 
Officer of CHBAH. The permission to use the data was also obtained from the database gate-
keepers. There was a separate approval from the HREC to collect data for clinical and audit 
purpose at the colposcopy clinic (M080603/M040609).  The storage of the information accrued 
was stored in password – protected computer. The Patient‟s permission to take part in the study 
was requested after they were given information on the study. There were three dedicated nurses 
and a doctor allocated to the clinic and they counselled patients after receiving their results. 
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Chapter 3 
3.0 Results 
This chapter describes the demographic factors of women who were recruited into the study. The 
histology and cytology will then be tabulated; it then describes the complications during and 
after the procedure.  The women‟s experiences and feelings about the procedure are described at 
the end of the chapter.  
 
3.1 Demographic data 
There were 150 women who were recruited between September 2014 to March 2015. These 
women were referred to colposcopy according to the national guidelines. The mean age was 
40.41(SD±9.51), with a range of 22-67 and the median was 40(IQR=34-46). The mean parity 
was 2.17(SD±1.34) with a range of (0-9) and the median parity was 2(IQR=1-3) 
 
3.2   Contraception use 
Condom usage was high in this group of women and a large number also used condoms with 
other methods as shown in the table 3.1 below. 
Table 3.1 A description of the type of contraception used n= (150) 
Type Frequency Percentage 
No Contraception 43 28.67 
Condoms only 59 39.33 
Depo Medroxyprogesterone Acetate 
and condoms 
12 8.00 
Norethisterone Enantate and condoms 5 3.33 
Implanon  and condoms 2 1.33 
COC and condoms 1 0.67 
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3.3 HIV infection 
There were 83(55.33%) women who were HIV positive, 37(24.67%) were negative, and   
30(20%) were unknown. The mean CD4 count was 366.90 cells/µl (SD±214.90), and the median 
was 328(IQR= 194 - 504), with a range of (24-964) . Of those patients who were HIV positive 
57(68.67%) were on ART, and 13(15.66%) were not on ART and there were 13(15.66%) in 
whom ART use was not known. 
3.4 Educational Background 
The highest level of education attained, was secondary school, with 136(90.67%)  having  
attained this, and 12(8.00%) had gone as far as a primary school level and 2(1.30%) had no 
schooling 
3.5 Relationship Status 
Most of women in this study were single as shown in table 3.2 below. Not all women answered 
the question on number of partners. Of the 108 patients who answered the question, the mean 
number of partners was 3.36(SD±2.93), and the median was 3 (IQR=1-4) with a range of 1-20. 
There were134 women who reported on their sexual debut. The mean age of sexual debut was 
18.29(SD±2.53).  The median age of sexual debut was 18(IQR=17-20) and the range was11-26. 
Table 3.2 Women‟s relationship status ( n=150) 
Relationship Frequency Percentage 
Cohabitating 4 2.67 
Divorced 8 5.55 
Married 31 20.67 
Single 97 64.67 
Widowed 10 6.67 
Total  150 100 
 
Tubal ligation and Condoms 2 1.33 
Tubal ligation only 1 0.67 
Total 150 100 
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3.6 Smoking 
Of the 120 women, where smoking was recorded, 12(10.00%) were smokers. 
 
3.7 Pap smear abnormalities at referral 
Table 3.3 shows Pap smear abnormalities at referral. There was one patient with a normal Pap 
smear. When the health worker thinks the cervix is suspicious the patient is referred to 
colposcopy irrespective of the cytology report. 
Table 3.3 Papsmear abnormalities at referral n= (150) 
Categories Frequency Percentage 
NORMAL 1 0.74 
ASCUS 4  2.96 
ASC-H 10 7.41 
 LSIL 18  12.00 
 HSIL 86 63.70 
 AGC 1 0.74 
 SUSPECTED INVASION 4  2.96 
 SQUAMOUS CELL 
CARCINOMA 
1  0.74 
NO RECORDS 25 16.67 
 
The following colposcopic diagnosis was made, 22(19.33%) had a CIN1, 50(43.48%) had a  
CIN2, 27(23.61%) had a CIN3, the data was not recorded in 10(8.70%) patients, and  3(2.61%) 
had  microinvasion and  there were  3(2.61%) patients in whom the colposcopy was thought to 
be normal. 
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3.8 Histology results after LLETZ 
Of the 144 women, two (1.39%) had normal histology results. CIN1 was diagnosed   in 
49(34.03%), CIN 2 in 35(24.31%), CIN 3 in 54(37.50%), Microinvasion in 1(0.69%) and 
malignancy in 3(2.08%) women. 
 
3.9 Margins on histology results after LLETZ 
The presence of disease at the margins of excision is an important predictor of recurrent or 
persistent disease in patients with cervical intraepithelial neoplasia 
Of 125 patients, 58(46.03%) had the lesion completely excised. The lesion was present at  
ectocervical margin in 32(25.31%) women, at the endocervical margin in 8 (4.88%) women and 
at  both margins in  21(16.67%) , The presence of the lesion was  not reported by NHLS in 
6(4.88%) women. 
  
3.10 Pain during the procedure 
Most women 139(93.29%), did not have pain and 134(89.33%) did not have any discomfort. 
Table 3.4 below shows the proportion of women who had  pain. Using the VAS pain scale for 10 
patients with pain: the mean pain was 4.78(SD±2.91) and the median was 4( IQR=2-10) with a 
range of 1-10. We then categorised the pain into mild(1-3), moderate(4-6) and severe pain (7-
10). Four (2.68%) patients had mild pains, 3(2.01%) had moderate pain, and 2(1.34%) women 
had severe pain. There was nothing that destinguishes the 2 patients with high pain scores from 
the rest of the patients. They were 30 years and 45 years old, neither of them had pain after and 
one had CIN3 (completely excised) and one had CIN2 (with a positive ectocervical margin) on 
their final histology. 
There were 34(22.67%) women who had a history of dysmenorrhea. Women who had 
dysmenorrhea as a symptom were more likely to have pain during the procedure 6(60.00%) 
versus 4(40.00%) with p-value=0.01). 
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Table 3.4 Pain or discomfort experienced during the procedure (n=150) 
Variable Responses Frequency Percentage 
Pain No 139 92.67% 
Unsure 2 1.33% 
Mild 4 2.67% 
Moderate 3 2.00% 
Severe 2 1.33% 
Discomfort no 134 89.33% 
yes 16 10.67% 
 
3.11 Pain after the procedure 
One hundred (66.67%) did not experience any pain, 50(33.33%) had pain. Of those who had 
pain, the pain was mild in 26(17.33%), moderate in 16(10.67%) and severe in 8(5,33%) women. 
The   mean pain was 4.32(SD±2.74) and the median was 3.5(IQR=1-10) with a range of (1-10) 
on the VAS scores. 
The pain occurred for a mean of  9.24 days(SD± 10.12) and a median of 3.5days (IQR=2-4) with 
a range of 1-28. 
There was no statistically significant difference between dysmenorrhea and pain after the 
procedure with 15(44.12%) patients with dysmenorrhea having pain after the procedure and 
35(30.17%) without dysmenorrhea having pain after the procedure(p-value=0.15) 
Of the fifty women who had pain after the procedure, 27(54.00%) took nothing for pain, 
14(28.00%) took paracetamol, 7(14.00%) took anti-inflammatory drugs, 1(2.00%) took aspirin 
only, and 1(2.00%) took both anti-inflammatory drugs and paracetamol 
 
3.12 The frequency and type of discharge before the procedure 
Women were asked if they had an abnormal discharge. Table 3.5 outlines the frequency and type 
of discharge experienced by women prior to the procedure, 87(58.00%) had no discharge, 
37(24.67%) had a white discharge, 14(9.33%) had a yellow discharge, 7(4.67%) had a brown 
discharge, 2(1,33%) had a green discharge, 2(1,33%) had a clear discharge and 1(0.67%) was 
unsure about the type of discharge. In terms of consistency, 18(12%) had a watery discharge, 
15(10.00%) had a thin and 30(20.00%) had a thick discharge 
34 
 
The mean length of time that women had had this discharge was 19.29(SD±24.78), days and a 
median of 14(IQR=5-28) with a range of 1-168) 
Table 3.5 Consistency of discharge before procedure (n=150)  
Consistency Frequency Percentage 
No discharge 87 58.00 
Watery 18 12.00 
Thin 15 10.00 
Thick 30 20.00 
Total 150 100 
 
 
3.13 Discharge after the procedure 
Women were again asked if they had abnormal discharge after the procedure. (Table 3.6) 
outlines the type of discharge after the procedure. There was no reported discharge in 
56(37.00%), 33(22.00%) had a yellow discharge, 34(22.67%) had a brown discharge, 3(2.00%) 
had a red discharge, 9(6.00%) had a clear discharge, 13(8.67%) had a white discharge, and 
2(1.33%) had a green discharge. 
Regarding the consistency of the discharge after the procedure, 61(40.63%) had a watery 
discharge, 23(15.33%) had a thick discharge, and 10(6.67%) had a thin discharge. 
The mean length of time of the discharge in days was 13.41(SD± 9.65), the median time was 10 
(IQR=5-21) with a range of (2-28). 
Overall there was no significant difference between subjects that had discharge before 
(63(42.00%)) and after the procedure (94(62.67%)) (P value=0.0590) and this is outlined in table 
3.6 
Table 3.6 A description of the type of discharge after the procedure n= (150) 
Type Frequency Percentage 
No discharge 56 37.00 
Yellow 33 22.00 
Brown 34 22.67 
Red 3 2.00 
Clear 9 6.00 
White 13 8.67 
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Green 2 1.33 
Total  150 100 
 
3.14 Menstrual history prior to the LLETZ procedure 
The menstrual histories  of women in this study were that, 73(48.67%) had  normal menstruation, 
37(24.67%) were menopausal, 32(21.33%) had hormone related amenorrhea either due to 
Medroxy progesterone acetate(DMPA)  or  Norethisterone  enantate , 7(4.67%) had irregular 
periods and 1(0.67%) was unsure of her menstrual history. 
 
3.15 Bleeding 
There were no women who had bleeding during the procedure that needed vaginal packing or  
admission. 
There were 121 (80.67%) who had bleeding after the procedure. The mean number of days that 
women had bleeding was 8.44(SD±7.67) and the median was 5(IQR=3-4) with a range of 1-28. 
The mean number of pads used per day(taking the highest number per day was 2.83(SD±3.90) 
and the median was 2(IQR=1-3), with a range of 1-40. 
There were 6(4.02%) who had to consult a health care practitioner because of bleeding. Of these,  
3(2.48%) patients didn‟t specify the form of treatment they received, 1(0.67%) was admitted and 
transfused, 2(1.34%) of the patients were seen at the local clinic, and received  Levonogestrel® 
and Ovral (Ethinyl estradiol 50µg and Levonogetrel 20µg) respectively 
 
3.16 Emotions that women experienced at the first visit to the colposcopy clinic. 
There were 85 (56.00%) who were worried about the procedure and the results. One woman 
(1.18%) worried because her mother died of cancer of the womb, 8(9.41%) were worried about 
the colposcopy procedure ,3(3.53%) were worried because they did not know what to expect,  24 
(28.24%) were worried about cancer, 46(54.12%) were “just worried” about the results, 
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1(1,12%) thought something was wrong with her, 2(2.35%) were worried because they thought 
that they would have to have a hysterectomy. 
 
The post procedure visit (after 4 week visit): 
Most women (135( 90% ))  were feeling happy about the results, however there were, 12(8.00%) 
said they were “relieved”, 1(0.67% ) felt bad because she was told that  had a cancer,1(0.67%) 
was stressed,1(0.67%)  was unsure because the specimen lacked transformation zone. 
 
3.17 Fear at colposcopy clinic 
Table 3.7 outlines fear among women at colposcopy, and the total percentage might not      
necessarily add up to hundred percent, as each woman reported more than one fear. 
                         Table 3 .7 A description of fear among women at colposcopy clinic (n=144) 
 
 
 
 
Fear Frequency Percentage 
Cancer 101 70.14 
Colposcopy 11 7.64 
Pain 6 4.17 
Hysterectomy 1 0.69 
Not knowing what to expect 4 2.44 
Infertility 15 10.45 
Leaving Kids behind 1 0.69 
Might have sexual problems 3 2.08 
No fear 27 18.75 
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3.18 Overall experience of colposcopy 
Of the 150 women, 149(99.33%) had good experience, which was attributed to prior counselling, 
1(0.67%) was bad ,“got shouted at by the nurse” 
144(96.00%) were pleased that they had the procedure under local anaesthesia, and 6(4.00%) 
would have preferred the procedure to be done in theatre under general anaesthesia  
All 150(100.00%) would advise a friend to have similar procedure if needed. 
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Chapter 4 
4.0 Discussion  
A „See and treat‟ clinic which combines colposcopic diagnosis and treatment is common in 
South Africa.
5
 This study is the first one locally, to look at the early complications and 
experiences of women after large loop excision of the transformation zone. In this chapter I will 
first discuss the main symptoms of pain, bleeding and discharge. I will then address women‟s 
fears and anxiety.  
Large loop excision of the transformation zone remains one of the commonest treatments of 
premalignant lesions  It is not without complications. Our patients reported bleeding, discharge 
and pain.   Despite the use of local anaesthesia, pain during the procedure was reported, with ( 
6.71%) having pain during, and ( 34.00%) after the procedure. There were 6(4.00%) who would 
have preferred to have the procedure under general anaesthesia. Overall the impression was good 
in that all of them would encourage a friend, to have the same procedure. When we quantified 
the pain there was only one woman who had severe pain. Other studies have shown similarly that 
few women have pain during the procedure. However pain after the procedure was reported in 
67% of women who had LLETZ in the study by Sharp et al.
31
 In this study, use of analgesia was 
never mentioned. 
A meta-analysis on pain control during outpatient treatment of cervical pre-malignant lesions, 
evaluated cervical injection with lignocaine alone, lignocaine with adrenaline, prilocaine with 
felypressin, oral analgesics (NSAIDS), inhalational analgesia (gas mixture of isoflurane and 
desoflurane), lignocaine spray, cocaine spray, local application of benzocaine 20% gel, EMLA 
cream and TENS. They concluded that cocaine spray before treatment resulted in better pain 
relief and a local anaesthesia combined with vasoconstrictor was associated with better pain 
control. They could not reach any conclusion regarding optimum sites of injection to inject, 
depth of injection and dosage of the agent used.71 
The commonest complication in our study was bleeding, with 121(80.67%) women reporting 
bleeding after the procedure, and only 1 patient was admitted and transfused. In the study by 
Sharp et al 
31
 87% of women had bleeding after the procedure, which is similar to what we 
found. 
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There was no statistical difference between women who had an abnormal discharge before 
(42.00%) and after the procedure (62.67%) (P-value=0.059). Overall there is still high 
prevalence of discharge after the procedure, which is consistent with the study by Sharp et al 
where 63.00% women had a discharge after the procedure.
31
However this is in contrary with a 
Nigerian study which reported discharge in 17.40% of women who had colposcopy and biopsy, 
and only one patient required admission for persistent discharge.
72 
We usually give our patients metronidazole for7 days after the LLETZ, and this is in contrast 
with two previous studies where they found no significant benefit or any reduction in morbidity 
after LLETZ unless there is evidence of growth on an endocervical swab.
73,74
 We postpone 
LLETZ in women with PID. The Australian and New Zealand guidelines do not recommend 
antibiotics during and after LLETZ procedure unless there are risk factors for pelvic 
inflammatory disease, and according to the guideline, they give doxycycline 100mg orally 60 
minutes before the procedure and then 200 mg 90 minutes after the procedure and Metronidazole 
500mg intravenously before the start of the procedure.
75 
Anxiety is a common symptom with screening tests. Increased levels of anxiety before and 
during colposcopy may lead to pain and discomfort during the procedure.
76 
In our study we 
looked at an overall anxiety, and we did not divide it into before and after the procedure. Other 
screening tests like transrectal ultrasound guided prostate biopsy have also been shown to be 
associated with  anxiety, with a quarter of the men reporting anxiety and other adverse effects if 
they felt inadequately prepared for the procedure.
76
 Two other studies in Thai and Swedish 
women found that 14% to 52% were anxious after colposcopy.
65,78
 There is also a study by T 
freeman et al which found that, level of anxiety was much higher in patients getting written 
information about see and treat versus information showed on videotapes before colposcopy.
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There is emerging evidence that the concerns of women post LLETZ might be cervical cancer, 
fertility and sexual issues.
65,78,79
 We found that 56.00% of patients said that they had been 
worried about the colposcopy. Very few of our patients were concerned about fertility and sexual 
function, with 4(2.67%) patients thought that they will not be able to fall pregnant again and the 
3(2.00) patients thought that they will not be able to have intercourse.  
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In our study most women (55.00%) were concerned about cancer, this is comparable to a 
Swedish prospective study, where they found that (52.00%) of patients feared that they had 
cancer and also had higher levels of anxiety.
78 
A Randomised controlled trial looking at immediate treatment versus biopsy and recall, found 
that women in the “see and treat” arm   had lower anxiety levels than defer and treat arm. 
Women in the “see and treat” arm also felt more relieved than women who in the “defer  and 
treat”.49 In the same study, women had good comments about see and treat, they believed that 
they had been treated without delay, not have to return to colposcopy clinic again and had 
psychological benefit of not being anxious while anticipating another procedure.49 
We did not measure anxiety levels using a score, we just asked about it. There are also studies 
which suggest that anxiety is on-going may be higher in women who were concerned about 
future cancer or future fertility.
50, 81, 82
 
Counselling just prior to the procedure is done at the local clinic on referral and by nurse 
practitioners at the colposcopy clinic. Despite counselling there were 85(56%) women who were 
worried, but most women (99.33%) had a good experience during the colposcopy. 
The majority of the patients in our study were HIV positive, this affirms the relationship between 
HIV and the high prevalence of cervical cancer precursor lesions. Twenty-five of our patients 
had CD4≤200 cells/µl. The threshold of putting patients on anti- retroviral treatment at the start 
of the study was about 350 cells/µl and currently is 500 cells/µl. SA has the world‟s largest 
antiretroviral therapy programme with approximately 1.8 million people having started ART by 
mid-2011.
83
 The number of women with unknown HIV status is of concern. After 2006 it 
became a protocol at this clinic to offer women an HIV test if their last test was more than 6 
months ago or if they did not know their HIV status.  There is still a stigma to being HIV 
infected and women may still refuse to be tested. More than 70% of patients were using 
contraceptives, which is more than what national data suggests, which is currently estimated to 
be 65%.
84 
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This is quite high considering that we had 20.95% women who were menopausal, this may also 
be that women are using condoms for prevention of HIV and STI‟s and not just for 
contraception.  
    
4.1 Limitation of the study 
This study was not without limitations. It was carried out in one institution, and the study period 
was also short. A sample size was not calculated as this was the descriptive study .The majority 
of patients were black Africans, which limits generalisation to other racial groups. The sample 
size was small; however it is similar to a Nigerian study which yielded almost similar results. 
Even though this data base is used clinically there was missing data. 
 
4.2 Recommendations 
The prevention of cervical cancer is complex, with screening, diagnosis and then treatment of 
precursor lesions. Explaining this process after the woman has received the results of an 
abnormal Pap smear is difficult. We are not sure about what counselling women received prior to 
having had a Pap smear. It is advisable that women are counselled on what an abnormal Pap 
smear may mean prior to the test.  
Some women might have poor knowledge and understanding of cervical cancer screening. 
Community education in newspapers and TV may also assist with understanding the screening 
process. 
 
4.3 Conclusion 
It should be remembered that treatment for premalignant lesions of the cervix reduces cervical 
cancer, but screening, colposcopy and treatment are associated with medical and emotional 
complications. 
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APPENDIX A 
 
 
DEMOGRAPHIC FACTORS 
 
Information to be retrieved from the database 
 
1. Age 
 
2. Parity 
 
 
3. Contraception: What contraception are you using at present? 
 
COC  
Injectable  
Condoms  
POP  
IUCD  
Sterilization  
Other  
 
4. HIV Status? 
     
5. Relationship 
Single  
Married  
Divorced  
Widowed  
Other  
                                 
6.   Any history of smoking?                               
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 7.    I want to ask you about your sexual life, if you are not comfortable don’t answer.  
a. Lifetime number of   Partners? 
b.  Age Sexual  Debut? 
 
8.  Discharge: was the discharge normal or abnormal?  
Before the procedure  
Yes/No  
How long in days   
colour Clear 
White 
Yellow 
Green 
Brown 
Other: 
 
 
offensive Yes 
no 
consistency Watery 
Thin  
Thick 
other 
 
9. Was there any discomfort during the procedure 
10.  Pain, during the procedure 
        During the procedure: quantify(VAS score) 
11. Menstrual  history 
      Last normal menstrual period? 
      Menopausal? 
 12.   Menstruation : 
         Do you have a pain during menstruation? 
        On which day is the worst? 
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Questions to be asked 4 weeks after the procedure: 
1.  Have you had a discharge in the last 4 weeks, was the discharge normal or abnormal? 
After  the procedure  
Yes/No  
How long in days  
colour Clear 
White  
Yellow 
Green 
Brown 
other: 
offensive Yes 
no 
Consistency Watery 
Thin  
Thick 
other 
 
       Did you have pain in the 4 weeks after the procedure? 
      How severe was the pain? 
      Did you have to take medication for the pain? 
       What did you take? 
      How long did it last? 
Have you had the need to go and see the doctor or go to the clinic for symptoms  that may have 
been related to the procedure? 
If yes explain; 
 
 2.  Bleeding 
            How many days did you bleed for after the procedure?  
             How heavy….quantify pads? 
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        Have you had a period  since the procedure? 
        If yes…was it different from the normal period 
                                   immediately, how many days? 
                                   How is it normally? 
3.  Were you anxious  or worried before your visit today…. Yes/no 
        What were anxious about?(was only asked at the last visit) 
 4.     How do you feel now that you have the results? 
    What was your biggest fear/ concern when you first came to the clinic:  
     fertility issues? 
     Sexual issues? 
    Cancer? 
    Other? 
 
5.  How would you describe your experience at this clinic?  
     If you had a friend with a similar problem would you advise them to have the same  
   Would you have preferred to have been under anaesthesia/ asleep? 
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APPENDIX D 
 
Information sheet 
Good morning, my name is Dr Titus Mooketse. I am a doctor in this hospital, specialising in 
Obstetrics and Gynaecology. I am doing a study entitled: “The short term complications and 
experiences of women after large loop excision of the transformation zone at Chris Hani 
Baragwanath academic Hospital”. 
Before you agree to participate it is important for you to read and understand what the study is 
about. You can ask me any questions that you may have at any time during the interview. Your 
participation is completely voluntary. Your treatment at this clinic will be the same whether you 
are in the study or not. 
Why are you being asked to participate?  
I would like to invite you to participate in this study because you have had LLETZ  . The doctors 
have given you the results and explained that you have to have to be followed up at this clinic. 
What the study is about: 
 We would like to find out if you have had any complications in the 4 weeks since LLETZ  and 
what your experiences with the procedure were. 
We also have three dedicated nurses and a doctor who provide counseling  after  receiving your 
results 
What is required for you to participate? I would like to interview you, the interview will take 
about 20 minutes. 
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We would also like to ask you some questions about the complaints that you may have in the 4 
weeks after the procedure, complaints may be bleeding , discharge or pain before you go home 
we would like to ask you about the bleeding , discharge and pain in the last 4 weeks..  
I would also like to give you a paper on which you can chart complaints that you may have in 
the 4 weeks. 
The questions that we ask now will take 5 minutes. 
Are there any risks for being in the study? There are no risk factors, you do not have to answer 
any questions if you are uncomfortable and you can stop the interview at any time. 
Will there be any benefits to being in the study? There will no be any direct benefits to you for 
being in the study. 
 Will this information be confidential? Yes the information will be completely confidential; the 
information will only be available to the researchers in this study. We intend to publish this 
study in the medical journal, but there will be no information by which you could be identified. 
You can contact me at any time in connection with the study. My name is Dr Titus Mooketse 
and my cell number is 0765291269 
If you have any questions regarding the Ethics of this study, you may contact Prof Cleaton- 
Jones on 011-717 1234  
If you are willing to be a participant in this study, kindly sign that you have understood all that 
has been explained to you and that you are a willing to take part in this study. 
 
Patient name: _____________________________ 
Patient signature: __________________________ 
Date:   2014 /__________/_____________ 
Witness: ____________________________________ 
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